ID   Lu-134-A
AC   CVCL_1387
AS   CVCL_2790
SY   Lu-134-a; LU-134-A; LU-134A; Lu-134A; Lu134A; LU-134; Lu-134; Lu134; NCC-c-Lu-134-A-H; Lu-134-A-H; LU-134-A-H; Lu-134-AH; LU-134-AH; Lu134-A-H; Lu134AH
DR   CLO; CLO_0050028
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471661
DR   CCLE; LU134A_LUNG
DR   Cell_Model_Passport; SIDM00296
DR   CGH-DB; 100-1
DR   CGH-DB; 9059-4
DR   ChEMBL-Cells; CHEMBL3308292
DR   ChEMBL-Targets; CHEMBL2366236
DR   Cosmic; 713881
DR   Cosmic; 753588
DR   Cosmic; 801604
DR   Cosmic; 809119
DR   Cosmic; 844808
DR   Cosmic; 876158
DR   Cosmic; 918005
DR   Cosmic; 929157
DR   Cosmic; 1212193
DR   Cosmic; 1219094
DR   Cosmic; 1239929
DR   Cosmic; 1571749
DR   Cosmic; 1995493
DR   Cosmic; 2125172
DR   Cosmic; 2668338
DR   Cosmic-CLP; 753588
DR   DepMap; ACH-002051
DR   GDSC; 753588
DR   GEO; GSM17310
DR   GEO; GSM1670063
DR   IARC_TP53; 1014
DR   JCRB; JCRB0235
DR   LINCS_LDP; LCL-1871
DR   LINCS_LDP; LCL-1877
DR   PharmacoDB; LU134A_865_2019
DR   RCB; RCB0466
DR   Wikidata; Q54903191
RX   DOI=10.5795/jjscc.24.451;
RX   PubMed=1312700;
RX   PubMed=1847845;
RX   PubMed=3022030;
RX   PubMed=6098504;
RX   PubMed=8286010;
RX   PubMed=9413215;
RX   PubMed=10358721;
RX   PubMed=11005564;
RX   PubMed=12107105;
RX   PubMed=15016488;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=23716474;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 46 hours (PubMed=3022030; PubMed=6098504); 51.9 hours (PubMed=8286010).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: TP53 p.Pro278Leu (c.833C>T) (PubMed=1312700).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.6%; Native American=0%; East Asian, North=73.6%; East Asian, South=23.8%; South Asian=1.7%; European, North=0.3%; European, South=0% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; JCRB; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9
ST   D16S539: 9
ST   D5S818: 11
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C4917; Small cell lung carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_1388 ! Lu-134-B
SX   Male
AG   80Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 26
//
RX   DOI=10.5795/jjscc.24.451;
RA   Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y.,
RA   Higuchi H., Uei Y.;
RT   "Analysis of LDH isoenzyme patterns in cell lines of the small cell
RT   carcinoma (lung) and retinoblastoma.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).
//
RX   PubMed=1312700;
RA   Sameshima Y., Matsuno Y., Hirohashi S., Shimosato Y., Mizoguchi H.,
RA   Sugimura T., Terada M., Yokota J.;
RT   "Alterations of the p53 gene are common and critical events for the
RT   maintenance of malignant phenotypes in small-cell lung carcinoma.";
RL   Oncogene 7:451-457(1992).
//
RX   PubMed=1847845; DOI=10.1007/BF00685110;
RA   Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T.,
RA   Saijo N.;
RT   "Prediction of the antitumor activity of new platinum analogs based on
RT   their ex vivo pharmacodynamics as determined by bioassay.";
RL   Cancer Chemother. Pharmacol. 27:263-270(1991).
//
RX   PubMed=3022030;
RA   Terasaki T., Shimosato Y., Nakajima T., Tsumuraya M., Morinaga S.,
RA   Hirohashi S., Yamaguchi K., Kato K., Ichinose H., Nagatsu T.;
RT   "Changes in cell characteristics due to culture conditions in cell
RT   lines from human small cell lung cancer.";
RL   Jpn. J. Clin. Oncol. 16:203-212(1986).
//
RX   PubMed=6098504; DOI=10.20772/cancersci1959.75.12_1089;
RA   Terasaki T., Kameya T., Nakajima T., Tsumuraya M., Shimosato Y.,
RA   Kato K., Ichinose H., Nagatsu T., Hasegawa T.;
RT   "Interconversion of biological characteristics of small cell lung
RT   cancer depending on culture conditions.";
RL   Gann 75:1089-1099(1984).
//
RX   PubMed=8286010;
RA   Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.;
RT   "Inhibitory effects of cholera toxin on in vitro growth of human lung
RT   cancer cell lines.";
RL   Anticancer Drug Des. 8:417-428(1993).
//
RX   PubMed=9413215;
RA   Yamane H., Kiura K., Tabata M., Bessho A., Tsuchida T., Motoda K.,
RA   Hiraki A., Ueoka H., Harada M.;
RT   "Small cell lung cancer can express CD34 antigen.";
RL   Anticancer Res. 17:3627-3632(1997).
//
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=12107105; DOI=10.1016/S0002-9440(10)64172-7;
RA   Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T.,
RA   Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S.,
RA   Inazawa J.;
RT   "A novel target gene, SKP2, within the 5p13 amplicon that is
RT   frequently detected in small cell lung cancers.";
RL   Am. J. Pathol. 161:207-216(2002).
//
RX   PubMed=15016488; DOI=10.1016/S0140-6736(04)15693-6;
RA   Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S.,
RA   Nakagawa K., Nomura H., Ishikawa Y.;
RT   "Two prognostically significant subtypes of high-grade lung
RT   neuroendocrine tumours independent of small-cell and large-cell
RT   neuroendocrine carcinomas identified by gene expression profiles.";
RL   Lancet 363:775-781(2004).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23716474; DOI=10.1002/gcc.22076;
RA   Iwakawa R., Takenaka M., Kohno T., Shimada Y., Totoki Y., Shibata T.,
RA   Tsuta K., Nishikawa R., Noguchi M., Sato-Otsubo A., Ogawa S.,
RA   Yokota J.;
RT   "Genome-wide identification of genes with amplification and/or fusion
RT   in small cell lung cancer.";
RL   Genes Chromosomes Cancer 52:802-816(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//